Eli Lilly experimental obesity drug Retatrutide hits up to 30% weight loss in pivotal trial
Eli Lilly (NYSE:LLY) announced historic topline results from its Phase 3 TRIUMPH-1 clinical trial, showing that its next-generation investigational drug, retatrutide, helped adults with obesity or overweight lose an average of up to 30.3% of their body weight.









-640x360.webp&w=3840&q=75)
